| Literature DB >> 36207044 |
Aya Katasako1, Sho Sasaki2,3,4,5, Yoshihiko Raita6, Shungo Yamamoto7,8,9, Kentaro Tochitani10, Minoru Murakami11, Ryo Nishioka12, Kiichiro Fujisaki1.
Abstract
OBJECTIVES: Elevated baseline serum alkaline phosphatase (ALP) may correlate with higher medium-term to long-term mortality in the general population and in patients with chronic kidney disease. However, few data are available on the association between serum ALP and the short-term prognosis of patients on haemodialysis (HD). We verified the association of ALP levels and bacteraemia or death in maintenance HD patients suspected of bacteraemia in an outpatient setting.Entities:
Keywords: dialysis; infectious diseases; nephrology
Mesh:
Substances:
Year: 2022 PMID: 36207044 PMCID: PMC9557305 DOI: 10.1136/bmjopen-2021-058666
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Study flow. After the sampling, 315 cases that met the eligibility criteria were included.
Figure 2Association between alkaline phosphatase (ALP) and bacteraemia or In-hospital death: logistic regression model. Multivariate analysis shown in this figure. There was no relationship between higher ALP and in-hospital death; however there was a statistically significant association between higher ALP and bacteraemia. Bacteraemia outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase, Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage In-hospital death outcome: Model 1, adjusted for age, sex; Model 2, adjusted for Model 1 + aspartate aminotransferase; Model 3, adjusted for Model 2 + vitamin D analogue use; Model 4, adjusted for Model 3 + haemodialysis vintage; Model 5, adjusted for Model 4 + presence of bacteraemia.
Baseline characteristics
| ALP≤360 U/L | ALP>360 U/L | Total | Missing (N) | |
| Age, years, median (IQR) | 73 (66, 80) | 72 (62, 79) | 73 (63, 80) | 0 |
| Sex | 0 | |||
| Males, n (%) | 77 (57.9) | 26 (48.1) | 178 (56.5) | |
| Females, n (%) | 56 (42.1) | 28 (51.9) | 137 (43.5) | |
| Diabetes mellitus, n (%) | 64 (48.1) | 27 (50.0) | 159 (50.5) | 0 |
| Systolic blood pressure, mmHg, median (IQR) | 134 (110, 150) | 134 (11, 150) | 134 (110, 150) | 2 |
| Diastolic blood pressure, mmHg, median (IQR) | 70 (60, 80) | 70 (60, 80) | 70 (60, 80) | 22 |
| Pulse rate, beats/minute, median (IQR) | 90 (78, 102) | 92 (84, 108) | 90 (78, 102) | 4 |
| Respiratory rate, per minute, median (IQR) | 20 (18, 24) | 20 (18, 24) | 20 (18, 24) | 43 |
| Body temperature, °C, median (IQR) | 37.3 (36.5, 38.0) | 37.6 (36.9, 38.3) | 37.2 (36.5, 38.0) | 6 |
| Laboratory data | ||||
| WBC (×103/µL), median (IQR) | 8.7 (6.2, 12.4) | 8.6 (6.1, 11.3) | 8.4 (6.2, 12.0) | 2 |
| ALP (U/L), median (IQR) | 237 (203, 280) | 502 (404, 780) | 271 (219, 376) | 128 |
| AST (U/L), median (IQR) | 17 (12, 25) | 24 (18, 55) | 18 (13, 25) | 7 |
| ALT (U/L), median (IQR) | 10 (7, 15) | 18 (12, 38) | 11 (7.5, 17) | 7 |
| T-Bill (mg/dL), median (IQR) | 0.5 (0.3,0.6) | 0.6 (0.4, 1.5) | 0.5 (0.3, 0.7) | 17 |
| Ca (mg/dL), median (IQR) | 8.8 (8.4, 9.3) | 8.7 (8.3, 9.4) | 8.8 (8.4, 9.4) | 93 |
| P (mg/dL), median (IQR) | 4.4 (3.3, 5.8) | 5.3 (4.1, 6.6) | 4.7 (3.8, 6.1) | 284 |
| CRP (mg/dL), median (IQR) | 5.2 (2.1, 11.2) | 6.0 (1.5, 12.3) | 5.5 (2.1, 12.1) | 31 |
| Haemodialysis vintage, months, median (IQR) | 51 (17.5, 114) | 58 (18, 139) | 55 (20, 115) | 14 |
| Vitamin D analogue use, n (%) | 60 (45.1) | 25 (46.3) | 134 (42.5) | 2 |
| Vascular access | ||||
| Arteriovenous fistula, n (%) | 86 (64.7) | 44 (81.5) | 130 (41.3) | 0 |
| Arteriovenous graft, n (%) | 11 (8.3) | 2 (3.7) | 13 (4.1) | 0 |
| Arteriovenous shunt, n (%) | 5 (3.8) | 2 (3.7) | 7 (2.2) | 0 |
| Temporary catheter, n (%) | 30 (22.6) | 6 (11.1) | 36 (11.4) | 0 |
The baseline characteristics of the cohort.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Ca, calcium; CRP, C reactive protein; P, phosphorus; T-Bil, total bilirubin; WBC, white blood cells.
Incidence of bacteraemia and in-hospital death in the total and groups stratified by ALP
| ALP≤360 U/L | ALP>360 U/L | Total | Missing | |
| Bacteraemia, | 20 (15.0) | 19 (35.2) | 50 (15.9) | 11 |
| In-hospital death, | 17 (12.8) | 9 (16.7) | 48 (15.2) | 22 |
The incidence of bacteraemia and in-hospital deaths in the total and groups stratified by ALP. The high-ALP group had a higher incidence of bacteraemia.
ALP, alkaline phosphatase.